EGLN3 and renal carcinoma: A recent report showed the silencing of PHD3 expression by CpG methylation in the promoter region of human cancer cell lines including renal cancer, prostate, breast and melanoma [12], and in plasma cells and B-cell lymphoma, suggesting PHD3 as a potential biomarker [35].